Description:
 
Background
It is difficult to achieve optimal exposure of all agents in combination therapy with drugs that exhibit different properties. Nanoparticle delivery systems are a well-known means to modify the pharmacokinetics and distribution of drugs. Northeastern researchers have demonstrated that through nanoencapsulation, similar pharmacokinetic profiles for drugs that exhibit drastically different half-lives without nanoencapsulation can be achieved. 
 
Technology Overview
In this invention, Northeastern researchers have developed a nanococktail comprised of two individual nanoparticle delivery systems.
The nanococktail is a mixture of two or more different nanoparticle formulations engineered in a manner such that they can be titrated to achieve the optimal dose in a single suspension. The nanococktail consists of any combination of nanoformulations based on the number of pharmaceutical agents to be delivered. The nanoformulations in the cocktail is either polymer-based, lipid-based, or metallic‑based material. The formulations in the nanococktail can deliver any pharmaceutical agent including small molecules and DNA or RNA based therapeutics. The formulations were tailored for the individual compounds but also designed such that they would be stable in the cocktail. The nanococktail is comprised of two different nanoparticle formulations to allow dosing of both drugs at the same time. The individual formulations in the nanococktail must be designed to have a similar surface charge to prevent aggregation upon mixing.
 
Benefits
- Formulations used in the nanococktail can significantly extend circulation half-life compared to previous reports
- The nanococktail of the same drugs administered at the same dose significantly slows tumor progression in a murine model
- Nanococktail is less toxic because fewer drugs can be administered to achieve the desired therapeutic response
Applications
- Treatment of cancer, specifically breast, ovarian, pancreatic, lung, or prostate cancers
- Can be used in conjunction with traditional chemotherapy 
 
Applications
- Treatment of cancer, specifically breast, ovarian, pancreatic, lung, or prostate cancers
- Can be used in conjunction with traditional chemotherapy 
 
Opportunity
- License
- Research collaboration
- Partnering
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Paige Baldwin
Srinivas Sridhar
Bijay Singh
Keywords:
Combination therapy
Drug Delivery
Nanomedicine
Therapeutic
Treatment